Global Oncology Biosimilars Market Size
Pharmaceuticals

How Will The Oncology Biosimilars Market Grow In 2022?

The reports have been updated with the most recent Ukraine-Russia War impact on market growth for all 27+ industries. The reports also provide possible solutions and opportunities for surviving this crisis.

 

Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies!

 

The oncology biosimilars market is forecasted to achieve exponential growth in the coming few years with a forecast CAGR (compound annual growth rate) of more than 28%, as per The Business Research Company’s market report!

 

Read More On The Oncology Biosimilars Market Report 2022 – https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

 

The Oncology Biosimilars Market Size In 2022 And Forecast

The global oncology biosimilars market is expected to grow from $3.27 billion in 2021 to $4.19 billion in 2022 at a compound annual growth rate (CAGR) of 28.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The oncology biosimilars market is expected to reach $11.35 billion in 2026 at a CAGR of 28.3%.

 

The oncology biosimilars market consists of sales of medicine and drug related products for cancer treatment.

 

Request for A Sample Of The Global Oncology Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2821&type=smp

 

Increased Number Of Expiration Of Biologics Patents Used For The Treatment Of Cancer Is Driving The Growth Of The Oncology Biosimilars Market

According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.

 

Competitive Landscape And The Regional Analysis Of The Oncology Biosimilars Market

Major players in the oncology biosimilars market are Biocoin, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan and F Hoffmann-La Roche.

 

Additionally, as per TBRC’s research – North America was the largest region in the oncology biosimilars market in 2021 holding the largest market share and The Middle East is expected to be the fastest-growing region in the forecast period.

 

The Oncology Biosimilars Global Market Report 2022 covers regional data on key drivers, opportunities, and strategies for the seven major regions of the world that are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The report includes market size and forecast market shares for all the regions and countries with respect to the major players of the oncology biosimilars market.

 

Increasing Investments In Research And Development – A Key Trend In The Oncology Biosimilars Market

Pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting growth potential of rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars.

 

Oncology Biosimilars Market Segmentation By The Business Research Company

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Others

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

 

Here Are Some Reports Related To The Oncology Biosimilars Market –

Biosimilar Monoclonal Antibodies Global Market Report 2022

Rituximab Biosimilars Global Market Report 2022

Biosimilar Lymphocyte Modulator Global Market Report 2022

 

Get In Touch With Us – Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

 

Found this article helpful? Share it on: